A recent case–control study on a large cohort of patients subjected to multigene panel testing further suggest that ATM and CHEK2 are associated with moderate breast cancer risk 18, providing support to NCCN recommendations for an annual magnetic resonance screening of these mutation carriers, starting at age 40 44. Here, ATM is linked to breast carcinoma.